Comparison of Serum Human Epididymis Protein (HE4), Carbohydrate Antigen 125(CA125) and Risk of Ovarian Malignancy Algorithm (ROMA) as Markers in Ovarian Cancer: A Systematic Review and a Meta-analysis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Indian Journal of Gynecologic Oncology

• Publication date

  2018-01-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40944-017-0174-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer

  2016cited by this paper
• The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients

  2015cited by this paper
• DIAGNOSTIC VALUE OF HE4, CA125 AND RISK OF OVARIAN MALIGNANCY ALGORITHM IN DETECTING OVARIAN CANCER

  2015cited by this paper
• Assessment of Hearing Loss by OAE in Asphyxiated Newborns

  2014cited by this paper
• Preoperative Evaluation of Risk of Ovarian Malignancy Algorithm Index in Prediction of Malignancy of Adnexal Masses

  2014cited by this paper
• Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.

  2014cited by this paper
• HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer

  2014cited by this paper
• Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium

  2014cited by this paper
• Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.

  2013cited by this paper
• Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis.

  2013cited by this paper
• Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: A meta-analysis

  2012influential reference
• Cancer Statistics, 2011: The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths

  2012cited by this paper
• Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis.

  2012cited by this paper
• Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass

  2011cited by this paper
• Human Epididymis Protein 4 (HE4) as a Serum Tumor Biomarker in Patients With Ovarian Carcinoma

  2011cited by this paper
• Mathematical Model Identifies Blood Biomarker–Based Early Cancer Detection Strategies and Limitations

  2011cited by this paper
• The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?

  2011cited by this paper
• The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?

  2011cited by this paper
• A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers.

  2007cited by this paper
• How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above.

  2007cited by this paper
• Summary and discussion of session recommendations.

  2006cited by this paper
• Comprehensive analysis of HE4 expression in normal and malignant human tissues

  2006cited by this paper
• Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

  2005cited by this paper
• Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.

  2005cited by this paper
• A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy.

  2005cited by this paper
• New tumor markers: CA125 and beyond

  2005cited by this paper
• Conducting systematic reviews of diagnostic studies: didactic guidelines

  2002cited by this paper
• Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

  2000cited by this paper
• Cancer statistics

  1989cited by this paper
• Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas.

  1986cited by this paper
• CLINICS 2012;67(5):437-441 DOI:10.6061/clinics/2012(05)06 CLINICAL SCIENCE

  year unknowncited by this paper

• Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women.

  2022cites this paper
• Diagnostic Models Combining Clinical Information, Ultrasound and Biochemical Markers for Ovarian Cancer: Cochrane Systematic Review and Meta-Analysis

  2022cites this paper
• The combined detection of ovarian cancer biomarkers HE4 and CA125 by a fluorescence and quantum dot dual-signal immunoassay

  2019cites this paper
• Diagnostic performance of biomarkers for ovarian cancer

  2019cites this paper